

SUPPLEMENTARY DATA

Supplementary Figure 1. Intraperitoneal injection of high-dose Aβ42 has no significant effect on body weight, food intake and liver function in C57BL/6J mice. *A*: Body weight of 10-week-old male C57BL/6J mice injected with PBS or high-dose Aβ42 (50 μg/mice, twice a day) for 9 days (n = 12 for each group) and 19 days (n = 11-12 for each group). *B*: Food intake of 10-week-old male C57BL/6J mice injected with PBS or high-dose Aβ42 (n = 11-12 for each group). *C*: Plasma alanine transaminase (ALT) and aspartate transaminase (AST) activity in the male C57BL/6J mice injected with PBS or high-dose Aβ42 (n = 6 for each group). Aβ42(H), high-dose Aβ42. Data are presented as mean and s.d.




Supplementary Figure 2. Intraperitoneal injection of high-dose Aβ(42-1) has no significant effect on fasting blood glucose level, insulin sensitivity, body weight, food intake and liver function in C57BL/6J mice. *A*: Fasting blood glucose levels of 10-week-old C57BL/6J mice injected with PBS or high-dose Aβ(42-1) (50 µg/mice, twice a day) for 9 days (n = 9-10 for each group). Fasting blood glucose levels were measured in mice fasted overnight for 14 h. *B*: Insulin tolerance test of 10-week-old C57BL/6J mice injected with PBS or high-dose Aβ(42-1) for 19 days (n = 9-10 for each group). *C*: Area under the curve (AUC) of insulin tolerance tests in B. *D*: Body weight of 10-week-old male C57BL/6J mice injected with PBS or high-dose Aβ(42-1) for 9 and 19 days (n = 9-10 for each group). *E*: Food intake of 10-week-old male C57BL/6J mice injected with PBS or high-dose Aβ(42-1) (n = 9-10 for each group). *F*: Plasma alanine transaminase (ALT) and aspartate transaminase (AST) activity in the male C57BL/6J mice injected with PBS or high-dose Aβ(42-1) (n = 3-4 for each group). Data are presented as mean and s.d.




SUPPLEMENTARY DATA

Supplementary Figure 3. Intraperitoneal injection of low-dose Aβ42 has no significant effect on body weight, food intake and liver function in C57BL/6J mice. *A*: Body weight of 10-week-old male C57BL/6J mice injected with PBS or low-dose Aβ42 (12.5 µg/mice, twice a day) for 17 and 25 days (n = 12 for each group). *B*: Food intake of 10-week-old male C57BL/6J mice injected with PBS or low-dose Aβ42 (n = 12 for each group). *C*: Plasma alanine transaminase (ALT) and aspartate transaminase (AST) activity in the male C57BL/6J mice injected with PBS or low-dose Aβ42 (n = 6 for each group). Aβ42(L), low-dose Aβ42. Data are presented as mean and s.d.



Supplementary Figure 4. Intraperitoneal injection of low-dose Aβ(42-1) has no significant effect on fasting blood glucose level, insulin sensitivity, body weight, food intake and liver function in C57BL/6J mice. A: Fasting blood glucose levels of 10-week-old C57BL/6J mice injected with PBS or low-dose Aβ(42-1) (12.5 µg/mice, twice a day) for 17 days (n = 12 for each group). Fasting blood glucose levels were measured in mice fasted overnight for 14 h. B: Insulin tolerance test of 10-week-old C57BL/6J mice injected with PBS or low-dose Aβ(42-1) for 25 days (n = 11-12 for each group). C: AUC of insulin tolerance tests in B. D: Body weight of 10-week-old male C57BL/6J mice injected with PBS or low-dose Aβ(42-1) for 17 and 25 days (n = 11-12 for each group). E: Food intake of 10-week-old male C57BL/6J mice injected with PBS or low-dose Aβ(42-1) (n = 12 for each group). F: Plasma alanine transaminase (ALT) and aspartate transaminase (AST) activity in the male C57BL/6J mice injected with PBS or low-dose Aβ(42-1) (n = 6 for each group). Data are presented as mean and s.d.



SUPPLEMENTARY DATA

Supplementary Figure 5. Injection of neutralizing antibody against Aβ for 1 week has no significant effect on fasting blood glucose level and hepatic JAK2/STAT3/SOCS1 signaling in APP/PS1 AD model mice. *A*: Fasting blood glucose levels of APP/PS1 mice intraperitoneally injected once with control IgG, 1H3 or 6C8 anti-Aβ neutralizing antibody for 1 week (n = 4-5 for each group). The fasting blood glucose levels were measured after fasting for 4 h. *B*: Immunoblot analysis of liver JAK2 and STAT3 phosphorylation states and SOCS-1 protein levels in APP/PS1 mice injected once with control IgG, 1H3 or 6C8 anti-Aβ neutralizing antibody for 1 week. *C*: Quantification of phosphorylated JAK2 and STAT3 levels and SOCS-1 protein levels in (B). All the protein levels were normalized to tubulin. Data are presented as mean and s.d.

